FAQs
The LucentAD® Complete test measures 5 biomarkers associated with Alzheimer’s Disease. The presence of phosphorylated tau protein (pTau217) in the blood is correlated with the presence of amyloid pathology in the brain, a hallmark of Alzheimer’s disease. Other biomarkers that are measured include Amyloid Beta 40 and 42, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL). Taken together the biomarkers give a 90% accuracy value and also a 90% chance that a patient will receive a clinically useful result, helping your healthcare provider to determine the likelihood of amyloid pathology.
If you are experiencing memory issues, you should talk to your healthcare provider and ask if the LucentAD® Complete test is right for you.
Individuals with a family history of Alzheimer's disease may be at a higher risk. You should consult your healthcare provider about whether you should get tested.
You can either book directly on this site or ask your healthcare provider to do this for you. It is recommended that the LucentAD® Complete blood test is part of a specialist appraisal by your doctor, which might also include clinical examinations and other tests.
A healthcare worker will collect a small amount of blood from a vein in your forearm using a standard collection vial. Your blood test sample will be sent to the USA where Lucent Diagnostics (Part of the Quanterix Corporation, provider of the LucentAD® Complete test) will perform analysis of your sample in their accredited laboratory.
When your results are ready, Advance Tests will notify you by email with a secure link to access your report.
The LucentAD® Complete test lab report will give you a risk of your having amyloid plaques in the brain, which is a hallmark of Alzheimer’s Disease. Results are classified into low, intermediate and high risk of amyloid pathology. Although a result indicating a high risk of amyloid pathology is consistent with Alzheimer’s Disease, it should not be used as a stand-alone diagnostic test but used as part of a full evaluation that may include clinical history and other tests. A low chance of amyloid pathology is likely to indicate a low risk of Alzheimer’s Disease but you may need to discuss with your healthcare provider if you are still experiencing memory issues. Only around 10% of patients receive an intermediate result. In this instance you may wish to discuss with your healthcare provider whether further testing is required, or whether a 'wait and see' approach is better for you. In all circumstances your healthcare provider is best placed to discuss your report with you, answer any questions, and plan next steps of your care.
Alzheimer’s disease is the most common cause of dementia, a general term for memory loss and other cognitive issues serious enough to interfere with daily life. Alzheimer’s disease accounts for 60-80% of dementia cases.
More Information
Questions
If you have any questions, please contact us.